Abiraterone suppresses irradiated lung cancer cells-induced angiogenic capacities of endothelial cells
T Ruan, L Jiang, J Xu, J Zhou - Journal of Bioenergetics and …, 2021 - Springer
Non-small cell lung cancer (NSCLC) threatens human life globally with high morbidity and
mortality and radiotherapy is one of the most effective methods for the treatment of NSCLC …
mortality and radiotherapy is one of the most effective methods for the treatment of NSCLC …
Implementation of Quality by Design Approach for Optimization of RP-HPLC Method for Quantification of Abiraterone Acetate in Solid Dispersion in Forced …
M Choudhari, MR Donthi, S Damle… - Current …, 2022 - ingentaconnect.com
Background: Abiraterone acetate is a derivative of steroidal progesterone, used as a firstline
therapy for metastatic castration of prostate cancer. Objectives: The present study …
therapy for metastatic castration of prostate cancer. Objectives: The present study …
[PDF][PDF] DEVELOPMENTS IN PROSTATE CANCER THERAPY: FROM THE ANDROGEN RECEPTOR TO ANTIANDROGENS AND BEYOND.
I Prutianu, ID CĂRUNTU, MB Manole, SE GIUȘCĂ… - …, 2021 - farmaciajournal.com
Prostate cancer is the second most common malignancy in men. The androgenic receptor
(AR) is the main therapeutic target for this type of cancer, hormone therapy being the …
(AR) is the main therapeutic target for this type of cancer, hormone therapy being the …
Abiraterone, a rare cause of severe perioperative hypokalemia with unusual presentation as aphonia and quadriparesis: a case report
S Thakore, A Kaasat, N Thakore… - Ain-Shams Journal of …, 2023 - Springer
Abstract Background Oral Abiraterone acetate is a novel antineoplastic agent approved by
the FDA for the treatment of metastatic prostate cancer. Abiraterone is an irreversible …
the FDA for the treatment of metastatic prostate cancer. Abiraterone is an irreversible …
[HTML][HTML] Abiraterone-Induced Hypokalemia: A Case Report
BI Nkwocha, M Singh - Cureus, 2023 - ncbi.nlm.nih.gov
Abiraterone, an androgen biosynthesis inhibitor drug approved by the Food and Drug
Administration (FDA) in 2011 for the treatment of metastatic prostate cancer, has seen an …
Administration (FDA) in 2011 for the treatment of metastatic prostate cancer, has seen an …
[HTML][HTML] Computational insight into crucial binding features for metabolic specificity of cytochrome P450 17A1
CZ Ai, HZ Man, Y Saeed, DC Chen, LH Wang… - Informatics in Medicine …, 2019 - Elsevier
In present study we aimed to explore the possible structural feature of Cytochrome P450
(CYP) 17A1 that contributes to the metabolic specificity. The predicable 3D-QSAR …
(CYP) 17A1 that contributes to the metabolic specificity. The predicable 3D-QSAR …
Cancer de la prostate et COVID-19: rôle des androgènes dans l'infection virale au SARS-CoV-2 et le développement de la COVID-19
A Hantute-Ghesquier - 2023 - theses.hal.science
La pandémie de COVID-19 compte plus de 600 millions de cas recensés dans le monde et
a fait plus de 6 millions de morts (chiffres en septembre 2022). Il a été constaté que les …
a fait plus de 6 millions de morts (chiffres en septembre 2022). Il a été constaté que les …
Effect of Dexamethasone on Abiraterone Pharmacokinetics in Mice: Determined by LC/MS Analysis
S Deb, M Ben-Eltriki, H Adomat, MY Chin… - Medicines, 2023 - mdpi.com
Background: Abiraterone acetate is a cytochrome P450 17A1 (CYP17A1) inhibitor that is
indicated for use in both castration-resistant and castration-sensitive prostate cancer …
indicated for use in both castration-resistant and castration-sensitive prostate cancer …
Abiraterone-Induced Hypokalemia: A Case Report
N Bernard, M Singh - Cureus, 2023 - search.proquest.com
Abiraterone, an androgen biosynthesis inhibitor drug approved by the Food and Drug
Administration (FDA) in 2011 for the treatment of metastatic prostate cancer, has seen an …
Administration (FDA) in 2011 for the treatment of metastatic prostate cancer, has seen an …
A Way for Finding Ligands for New Binding Sites
KA Shcherbakov, AV Veselovsky - Biomedical Chemistry: Research …, 2023 - bmc-rm.org
Abstract Analysis of protein structures shows that most of them have potential binding sites
that may be considered as applicable for new ligand design. The lack of known ligands …
that may be considered as applicable for new ligand design. The lack of known ligands …